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Crystal structure of human branched-chain α-ketoacid
dehydrogenase and the molecular basis of multienzyme
complex deficiency in maple syrup urine disease
Arnthor Ævarsson1†, Jacinta L Chuang2, R Max Wynn2, Stewart Turley3,
David T Chuang2 and Wim GJ Hol1,3*
Background: Mutations in components of the extraordinarily large α-ketoacid
dehydrogenase multienzyme complexes can lead to serious and often fatal
disorders in humans, including maple syrup urine disease (MSUD). In order to
obtain insight into the effect of mutations observed in MSUD patients, we
determined the crystal structure of branched-chain α-ketoacid dehydrogenase
(E1), the 170 kDa α2β2 heterotetrameric E1b component of the branched-chain
α-ketoacid dehydrogenase multienzyme complex. 
Results: The 2.7 Å resolution crystal structure of human E1b revealed essentially
the full α and β polypeptide chains of the tightly packed heterotetramer. The
position of two important potassium (K+) ions was determined. One of these ions
assists a loop that is close to the cofactor to adopt the proper conformation. The
second is located in the β subunit near the interface with the small C-terminal
domain of the α subunit. The known MSUD mutations affect the functioning of
E1b by interfering with the cofactor and K+ sites, the packing of hydrophobic
cores, and the precise arrangement of residues at or near several subunit
interfaces. The Tyr→Asn mutation at position 393-α occurs very frequently in the
US population of Mennonites and is located in a unique extension of the human
E1b α subunit, contacting the β′ subunit. 
Conclusions: Essentially all MSUD mutations in human E1b can be explained
on the basis of the structure, with the severity of the mutations for the stability
and function of the protein correlating well with the severity of the disease for
the patients. The suggestion is made that small molecules with high affinity for
human E1b might alleviate effects of some of the milder forms of MSUD.
Introduction
The human branched-chain α-ketoacid (2-oxo acid)
dehydrogenase (BCKD) complex is a member of the
mitochondrial α-ketoacid dehydrogenase complex family
comprising pyruvate dehydrogenase, α-ketoglutarate
dehydrogenase, and BCKD complexes [1]. The multien-
zyme complexes in the family range in molecular mass
from 4 million to 10 million daltons and share the same
basic architecture, using numerous copies of three
enzymes as major building blocks, referred to as E1, E2
and E3. A dihydrolipoyl transacylase (E2) forms the core
of the complex with either 24 copies in octahedral sym-
metry or 60 copies in icosahedral symmetry depending on
the type and source of the complex [2–5]. Multiple
copies of an α-ketoacid dehydrogenase (E1), a dihy-
drolipoamide dehydrogenase (E3), and in some systems
of additional proteins, including a protein kinase and a
protein phosphatase [1], are attached to the E2 core
through non-covalent bonds. E2 is a dynamic multi-
domain protein with a large catalytic domain which forms
the core of the complex, plus a smaller binding domain
and one or more lipoyl domains linked to the core
through flexible linkers. The E2 binding domain is in
many cases responsible for binding E1 and/or E3 to the
core whereas the highly mobile lipoyl domain contains a
covalently bound lipoamide cofactor that is central to
substrate channeling within the multienzyme complex.
The α-ketoacid dehydrogenase multienzyme complexes
catalyze analogous reactions in central metabolism. An
α-ketoacid (pyruvate, branched-chain α-ketoacids or
α-ketoglutarate) is decarboxylated by the E1 component
followed by transfer of the remaining acyl group to the
lipoamide cofactor bound to E2. Next, the active site of
the E2 catalytic domain (in the core of the complex) cat-
alyzes the transfer of the acyl group from lipoamide to
coenzyme A (CoA) forming acyl–CoA and leaving the
lipoamide in a reduced state. Eventually, the E3 compo-
nent reactivates the lipoamide by oxidation using a bound
FAD cofactor and NAD+ as external electron acceptor,
Addresses: 1Department of Biological Structure,
University of Washington School of Medicine,
Seattle, Washington 98195, USA, 2Department of
Biochemistry, University of Texas, Southwestern
Medical Center, Dallas, Texas 75235, USA and
3Howard Hughes Medical Institute, University of
Washington, Seattle, WA 98195, USA.
†Present address: Prokaria Discovery, Keldnaholt,
IS-112 Reykjavik, Iceland.
*Corresponding author.
E-mail: hol@gouda.bmsc.washington.edu 
Key words: α-ketoacid dehydrogenase, α-ketoacid
dehydrogenase multienzyme complex, maple syrup
urine disease, Mennonite, thiamin diphosphate
Received: 31 August 1999
Revisions requested: 4 November 1999
Revisions received: 8 December 1999
Accepted: 22 December 1999
Published: 28 February 2000
Structure 2000, 8:277–291
0969-2126/00/$ – see front matter 
© 2000 Elsevier Science Ltd. All rights reserved.
Research Article 277
st8303.qxd  03/22/2000  11:31  Page 277
thereby completing the functional cycle of the multi-
enzyme complex [2,6].
The BCKD complex [7] is organized around a 24-meric
cubic core of the 46.7 kDa dihydrolipoyl transacylase (E2b)
with multiple (~6–12) copies of the 170 kDa branched-
chain α-ketoacid dehydrogenase (E1b), ~6 copies of the
110 kDa dimeric E3, and a small number of copies of the
E1b-specific kinase [8,9] and the E1b phosphatase [10].
The E1 component is a thiamine diphosphate (ThDP)-
dependent enzyme consisting of two 45.5 kDa α subunits
and two 37.8 kDa β subunits. Hence, the BCKD complex
consists of multiple copies of six different polypeptide
chains. After import into the mitochondrion and processing
of precursor polypeptides, these six proteins fold and
assemble, presumably with the assistance of chaperonins in
the mitochondrial matrix, into a multienzyme complex of
4–5 million daltons [11,12].
The particular importance of the structure determina-
tion of human E1b arises from the fact that the BCKD
complex catalyzes the oxidative decarboxylation of
branched-chain α-ketoacids (BCKA) derived from the
branched-chain amino acids (BCAA) leucine, isoleucine
and valine. In patients with autosomally inherited maple
syrup urine disease (MSUD), also called branched-chain
ketoaciduria, the activity of the BCKD complex is defi-
cient [13]. This results in the accumulation of BCKA and
BCAA in plasma, which has severe clinical consequences
including often fatal acidosis, neurological derangement
and mental retardation [14]. Variations in clinical presen-
tations have led to the classification of MSUD into five
distinct phenotypes, classic, intermediate, intermittent,
thiamin-responsive and dihydrolipoamide dehydroge-
nase-deficient [6]. The classic form, which comprises
75% of MSUD patients, is manifested within the first
two weeks of life and if untreated, lethargy, seizures,
coma and death ensue. Intermediate MSUD is associ-
ated with elevated levels of BCAAs and BCKAs, with
progressive mental retardation and developmental delay
without a history of catastrophic illness. An intermittent
form of MSUD might have normal levels of BCAAs,
normal intelligence and development until a stress, for
example an infection, precipitates decompensation with
acidosis and neurologic symptoms, which are usually
reversable with dietary treatment. Thiamine-responsive
MSUD is similar to the intermediate phenotype but
responds to pharmacological doses of thiamine with nor-
malization of BCAAs. The dihydrolipoamide dehydroge-
nase-deficient MSUD is caused by defects in the E3
component of the BCKD complex, which is shared with
the pyruvate and α-ketoglutarate dehydrogenase com-
plexes. Patients with dihydrolipoamide–dehydrogenase
deficiency have, therefore, a combined deficiency of all
three enzyme complexes, and usually die in infancy with
severe lactic acidosis [15].
To understand the molecular and biochemical basis of
MSUD, we have undertaken the determination of the
crystal structure of human E1b. In this report, we
describe the three-dimensional structure of this ThDP-
dependent enzyme at 2.7 Å resolution, which reveals
several unique structural features that are absent in the
homologous enzyme from Pseudomonas putida [16]. Most
significantly, the structure of human E1b provides
remarkable insights into the mechanisms by which
MSUD mutations affect the catalysis, folding and assem-
bly of this clinically important protein.
Results and discussion
Description of the structure
The overall heterotetrameric structure of human E1b is
shown in Figure 1. To a first approximation, the tetrameric
structure is a four-lobed entity with each lobe in the tetra-
hedral arrangement roughly corresponding to one of the
four subunits. Each subunit is in extensive contact with all
the other three subunits. Striking features of the subunit
interactions are the crossover of the N-terminal tails of the
α subunits, and the extended C-terminal domains of the
α subunits ‘holding onto’ the β subunits. The designation
of the subunits as α, α′, β and β′ has been chosen such that
the α subunit and the β subunit together correspond to
one polypeptide of the structurally similar but dimeric
yeast transketolase [17] and, by analogy, to one subunit of
the dimeric E1s of the α2 type [18].
Each 400-residue α subunit of human E1b is composed of a
large α/β domain (residues 1–355) with an extended N-ter-
minal tail (residues 1–30) and a small helical C-terminal
domain (residues 356–400). The central 14-stranded
β sheet in the major domain is buried by 13 helices in vari-
able orientations. The secondary structure elements in the
α subunit comprise a total of 12 strands and 15 helices
(Figures 1,2). Each β subunit of 342 residues is divided into
two similar sized domains corresponding to the N-and
C-terminal halves of the polypeptide, comprising residues
1–191 and 199–342, respectively. Both domains have an
α–β architecture comprising a central β sheet with several
helices packed against the sheet on both sides (Figures 1,2).
Structural comparison with homologous enzymes
The structure of human E1b provides an opportunity to
compare this eukaryotic enzyme with its bacterial homolog
in P. putida [16]. Superposition of the two structures gives a
root mean square (rms) deviation of 1.8 Å and a sequence
identity of 43% for the 658 structurally equivalent residues.
The most notable differences between the structures are
found at the N and C termini of the α subunits. The N-ter-
minal tail in each case crosses over and embraces the other
α subunit but does so in entirely different ways in the two
proteins. The 30-residue N-terminal tails of the α subunits
in the human E1b are intertwined in a ‘firm handshake’
whereas the corresponding tails in the P. putida structure
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extend to opposite sides on the tetramer far from crossing
each others’ path.
The small C-terminal domain of the human α subunit is
16 residues longer than its counterpart in P. putida
(Figure 2), resulting in a longer last helix and an irregular
tail. This extension in the human structure is the site of an
important mutation causing MSUD (Y393N-α; mutations
given using single-letter amino acid code) [19] and is criti-
cal for the structural integrity of the human E1b tetramer,
as will be discussed later. 
Human E1b and P. putida E1b share features with other
proteins in the superfamily of ThDP-utilizing enzymes
[16,17,20–22]. The common homologous region of these
proteins includes the cores of the α subunit and the N-ter-
minal domain of the β subunit. Comparison of the struc-
tures reveals how these common domains can have a
different order within the same polypeptide [21] or be dis-
tributed over different polypeptide chains as is the case in
the present structure.
Binding of the ThDP cofactor
The ThDP cofactors are bound in the two active sites of
the tetramer at the α–β′ and α′–β interfaces. The
sidechains of Gln112-α, Tyr113-α, Arg114-α, Arg220-α,
and His291-α and the mainchain atoms of Gly194-α and
Ala195-α in the α subunit are in direct contact with the
oxygen atoms of the phosphate groups of the cofactor
(Figure 3a). The associated magnesium ion is octahedrally
coordinated between the cofactor phosphates, the car-
bonyl of Tyr224-α, and the sidechains of Asn222-α and
Glu193-α. The sidechain of Tyr102-β′ is packed against
one side of the aminopyrimidine ring of the cofactor with
the sidechain of Leu164α approaching the other side of
the ring, wedged in between the two ring systems of the
cofactor. The sidechains of Ile226-α and Leu74-β′ also
contribute to cofactor binding through hydrophobic inter-
actions. Glu76-β′ is directly bound to the N1′ atom and
the carbonyl group of Ser162-α is bound to the N4′ group
on the opposite side of the aminopyrimidine ring. These
two interactions, as well as the coordination of the magne-
sium ion and the conformation of the cofactor (having
torsion angles ΦT = 100°, Φp = –71° in our structure), are
conserved features among proteins of known structure in
the ThDP superfamily and probably represent features of
functional significance [23–25].
The two serine residues that are phosphorylated in human
E1b are Ser292-α and Ser302-α. Inactivation of the
enzyme, and consequently of the whole complex, occurs
upon phosphorylation of Ser292-α at the primary site
[26,27], which is located close to the active site. The
primary site Ser292-α is next to the conserved His291-α,
which is directly involved in binding the cofactor phos-
phates and this histidine residue might also play a more
direct role in the catalytic mechanism [16,27]. Phosphory-
lation at Ser292-α most probably prevents substrate and/or
cofactor binding through steric hindrance or electrostatic
repulsion between the cofactor phosphates and the phos-
phate group introduced by phosphorylation. The function
of His291-α in cofactor binding or catalysis could also be
eliminated by the presence of an adjacent phosphate
group or by induced conformational changes involving the
loop comprising Ser292-α and His291-α. Given that this
loop is also found at the opening of the active-site
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Figure 1
Overall structure of the heterotetramer in two orthogonal orientations
rotated about the vertical axis. The secondary structure elements are
depicted as cylinders for helices and arrows for strands. The chain
termini in the different subunits are labeled N and C, and the four
subunits (α, purple; β, red; α′, blue; β′, yellow) are in ‘canonical’ colors
used throughout the paper. This figure was made with the help of
MOLSCRIPT [48] and the Raster3D suite [49].
st8303.qxd  03/22/2000  11:31  Page 279
channel, it is not unlikely that the binding sites for the
kinase and phosphatase and that of the E2 lipoyl domain
overlap to a certain degree.
Structural potassium ions
Initial examination of difference electron-density maps
showed the presence of two spherical peaks with high pos-
itive density at the 8–10σ level. These peaks were inter-
preted as monovalent metal ions for four reasons: firstly,
the peak heights were considerably above that of all other
water molecules, which rarely exceeded 5σ; secondly, the
number of surrounding atoms was 5 to 6, considerably
more than typically seen for water peaks; thirdly, the
groups in contact with the bound entity all contained an
oxygen atom; fourthly, when refined as a potassium ion
the B factors obtained reasonable values. Crystallization
conditions of human E1b included both 10 mM Mg2+ and
250 mM K+. The latter ions are of special interest because
Shimomura et al. [28] have shown previously that stability
and activity of the branched-chain dehydrogenase multi-
enzyme complex from rat liver is to a large extent depen-
dent on the presence of K+ with the E1 component being
the most probable site of metal binding. It was further
shown that stabilization of E1 by ThDP is dependent on
the presence of K+ and that stabilization by K+ ions is
likely to be physiologically relevant in vivo because the
mitochondrial matrix maintains a K+ concentration of
100 mM [28]. A similar dependence on K+ for stability is
also observed in human E1b [12]. The two positive differ-
ence map peaks in the human E1b structure were there-
fore interpreted as K+, which agrees with these
biochemical observations because they are bound in loca-
tions that are likely to be critical for the stability and func-
tion of the protein.
The K+ bound at site 1 (Figure 3b) stabilizes a loop con-
taining residues 161–166 of the α subunit. The residues in
the loop are well conserved among E1b proteins including
Ser161-α, Thr166-α and Gln167-α, which are directly
involved in ligating the metal ion through their sidechains.
Other atoms involved in coordination of the metal are
mainchain carbonyl oxygens of Ser161-α and Pro163-α.
The previously determined structure of P. putida E1b [16]
probably also contains a K+ at the corresponding position.
Interestingly, the structural integrity of the K+-binding
loop 161–166 is probably very critical for the activity of the
enzyme because the residues of this loop contribute
directly to cofactor binding by hydrophobic interactions,
through Leu164-α wedged between the two rings of the
ThDP, and by hydrogen bonding between the carbonyl of
Ser162-α and the 4′ amino group of the cofactor
(Figure 3b). Both these interactions are a conserved
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Figure 2
Annotated sequence alignment of P. putida and human E1b α and
β subunits. The sequences are shown with amino acid residues in red
for identical residues and black for non-identical residues. Residues
shown in italics have a very different conformation in the two structures
and are not structurally equivalent. Secondary structure elements in the
human E1b structure are shown with cylinders and arrows above the
sequences (purple in the α subunit and yellow in the β subunit). The
numbering of secondary structure elements is consistent with that
used for P. putida E1b [16]. Residues involved in binding the cofactor
ThDP and the associated magnesium ion are indicated by shaded
boxes. The sequence motif in the superfamily of ThDP-utilizing
enzymes is shown using black open boxes. Regions involved in K+
binding are shown with red open boxes and the two phosphorylation
sites are indicated by red arrows. Mutations identified as causing
MSUD are shown below the sequences in blue boxes.
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feature among ThDP-utilizing proteins with known struc-
ture [16,17,20–22]. The binding of the K+ ion at this posi-
tion to the α chain of E1b explains why enzyme activity as
well as stabilization of the protein by ThDP binding is
dependent on the presence of K+. 
The second K+-binding site is found in the β subunit at
the interface with the small C-terminal domain of the
α subunit (Figure 3c). The metal ion connects two
regions in the β subunit with residues Gly128-β,
Leu130-β, Cys178-β, Asp181-β and Asn183-β being
directly involved in binding the metal. The coordination
of the second K+ is octahedral and is almost exclusively 
maintained by carbonyl oxygens of the protein main-
chain, with only one sidechain (Thr131-β) indirectly
involved in metal binding through a water molecule. An
interesting feature of the metal ligation at this site is the
use of carbonyl atoms from the C terminus of an α helix,
utilizing the negative end of a helix dipole to interact
favorably with the positively charged metal ion
(Figure 3c). One of the regions stabilized by this second
K+ is directly involved in contacts with the α subunit
through the sidechain of Asn183-β, which makes a hydro-
gen bond with the mainchain imino group of Gln369-α.
The binding of K+ at this site is likely to be important for
the stability of the tetrameric E1b structure and agrees
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Figure 3
Cofactor and K+-binding sites in human E1b.
(a) Schematic representation of the cofactor-
binding site. Gln112-α and protein ligands of
the magnesium ion have been omitted for
clarity. (b) Potassium site 1 (α subunit). The
metal stabilizes a loop involved in cofactor
binding. The metal ion is bound by two
mainchain carbonyl groups and by the
sidechains of Ser161-α, Thr166-α and
Gln167-α. The sidechain of Leu164-α and
the mainchain carbonyl group of Ser162-α
make direct contact with the ThDP cofactor.
(c) Potassium site 2 (β subunit). The metal
binding at this site stabilizes regions in the
β subunit at the interface with the small
C-terminal domain in the α subunit. The metal
is octahedrally coordinated mainly by
mainchain carbonyl groups and interacts
favorably with the C-terminal end of a helix
dipole as indicated. Several sidechains
indicated by an asterisk have been omitted
for clarity. This figure was made with
LIGPLOT [50], MOLSCRIPT [48] and the
Raster3D suite [49].
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well with the observed dependence of the enzyme activ-
ity on the concentration of potassium salts [12,28].
Subunit interactions
The interactions between the four subunits in the
tetramer are extensive and consist of four different inter-
faces: first between the two α subunits (i.e. interface α–α′)
burying 3215Å2 solvent-accessible surface area; second,
the α–β interface burying an area of 1993Å2; third, the
α–β′ interface burying 1890 Å2; and fourth the β–β′ inter-
face shielding 2239Å2 from the solvent. The α–α′ inter-
action is to a large extent formed by the intertwining
N-terminal tails making the buried accessible surface area
substantially more extensive than in the P. putida E1b
structure (3215Å2 against 1915Å2). Overall, not less than
37% of the accessible surface of the α subunits and 46% of
the β subunits is devoted to subunit interactions. This
includes large hydrophobic patches that would be exposed
prior to tetramer assembly within the mitochondrion. This
is consistent with the requirement of chaperonins
GroEL/GroES for the assembly of the human E1b het-
erotetramer in Escherichia coli [11] and in vitro [12].
Analysis of E1b mutations causing MSUD
There are currently 19 known MSUD-causing mutations
that result in amino acid substitutions in the α and β sub-
units of human E1b (Table 1). With a few exceptions,
mutations in the α subunit of E1b are often associated
with the manifestation of the severe classic MSUD pheno-
type. The structure of human E1b can now be used to
divide the group of mutations into three subgroups on the
basis of the likely effect of each mutation on the structure
and function of E1b. The first group includes mutations
affecting cofactor binding, the second affects mainly
hydrophobic cores and the third occurs at subunit inter-
faces (Table 1). Table 1 provides information regarding
the residual BCKD complex activity, ethnic origin and the
clinical phenotype of homozygous or compound heterozy-
gous MSUD patients carrying the corresponding muta-
tions. With some exceptions, cells from classic MSUD
patients usually exhibit 0–2% of normal BCKD complex
activity, whereas cells from intermediate patients show
2–30% of normal BCKD complex activity. The location of
the corresponding mutations in the present structure can
now be used to explain these observations.
Mutations affecting cofactor binding
The MSUD-causing mutations that can be most easily
explained are substitutions of residues that are directly
involved in binding the cofactor in the active site.
Asn222-α is one of the residues in the consensus sequence
motif for this family of enzymes [29] and contributes to
cofactor binding by ligating the associated magnesium ion
(Figure 4a). Judged by the strict conservation of Asn222-α
within the family, this residue has a critical function, one
that can apparently not be performed by a serine residue
because the N222S-α mutation causes MSUD. The expla-
nation is probably that in wild-type human E1b, the
sidechain carbonyl oxygen of Asn222-α is used for binding
metal ions, whereas the hydroxyl group of the serine
sidechain would be a poorer ligand to the magnesium ion.
Moreover, the Oγ of a serine residue would not be able to
extend as far towards the magnesium ion as the Oδ1 of the
aspargine, which is another factor likely to decrease the
affinity for magnesium at this site. This is reflected by a
103-fold increase in KM for ThDP of Asn222S-α E1b com-
pared with the wild-type enzyme (data not shown). The
asparagine to serine mutation at position 222-α causes a
severe, ‘classic’, case of MSUD.
The severe R114W-α and R220W-α MSUD mutations
probably have quite similar effects on the cofactor-binding
site. Both substitutions introduce a tryptophan residue in
the place of an arginine residue directly involved in binding
the cofactor through ionic interactions with its phosphate
groups (Figure 4a). Besides loosing that capability, the
bulky tryptophan residue probably prevents the protein
from adopting a proper active-site conformation and could
even prevent cofactor binding by steric hindrance. Given
the major effects expected on ThDP binding, and possibly
substrate binding due to these mutations, it is not surpris-
ing that this causes the classic severe type of MSUD.
One of the more intriguing mutations is T166M-α
because it replaces a residue involved in ligation of K+ at
site 1. The probable abolishment of K+ binding at this site
by the T166M-α mutation is most probably caused by
destabilization of the loop forming the K+-binding site and
preventing this loop from adopting the precise conforma-
tion required for cofactor binding that involves Ser162-α
and Leu164-α at the tip of the loop (Figure 3b). The
result is a classic severe type of MSUD.
Mutations affecting hydrophobic cores
A part of the hydrophobic core in the main domain of the
α subunit is formed by the sidechains from helices 3 and
11 and strands a, d, e, h and i. Two mutations in the
α subunit seem to disrupt this hydrophobic core
(Figure 4b). Clearly, the large and charged sidechain of
arginine introduced by the T265R-α mutation in helix 11
cannot be accommodated within this core in the current
conformation. The site of the much less dramatic I281T-α
mutation in strand i is very close to Thr265-α. The I281T-α
substitution might seem subtle but a polar sidechain
might not be easily tolerated in this exclusively hydropho-
bic environment. In the family of heterotetrameric E1 pro-
teins (about 50 known sequences so far), only leucine,
methionine, isoleucine and valine are found at this posi-
tion. Patients heterozygous for I281T-α/Q145K-α show an
intermediate clinical phenotype and the corresponding
cells show low residual enzyme activity (Table 1). The
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relatively mild form of the disease in this case corresponds
well with the relatively small predicted effect of the muta-
tions on protein structure and stability.
Two mutations that also seem to prevent the formation of
an optimal hydrophobic core are G204S-α and A208T-α
(not shown). In both cases, the mutation introduces a
larger polar sidechain in an environment in which a
smaller and non-polar residue is required.
The M64T-α mutation in helix 2 appears to reveal a
remarkably critical spot in a hydrophobic core in the α
subunit at a location where four helices come together
through hydrophobic interactions (not shown). The con-
servation of this methionine residue within the family of
heterotetrameric E1b proteins suggests that it cannot be
easily replaced by the polar and smaller sidechain of a
threonine residue. Residual multienzyme complex activity
in cells from patients carrying this mutation is significant
and gives rise to an intermediate clinical phenotype
(Table 1), in agreement with the expected limited effect
of the methionine to threonine substitution at position 64-
α on E1b stability.
Mutations affecting subunit interactions
The extensive subunit interactions in the heterote-
trameric structure are undoubtedly crucial for maintaining
the catalytically active structure of the enzyme, because
the cofactor is bound at an α–β′ interface where residues
from both subunits form the active site. There are a
number of MSUD mutations that originate from their
detrimental effect on subunit–subunit interaction surfaces
(Table 1). Interestingly, all four different interfaces, α–α′,
α–β, α–β′ and β–β′, located at entirely different positions
throughout the heterotetramer, are effected by this class
of mutations, as will be discussed later.
A209D-α, A240P-α, G245R-α and R252H-α all cluster at
or close to the interface between the α subunits. This
α–α′ interface in the interior of the tetramer is to a large
extent formed by helix 10 in the two α subunits, which
associate around the twofold axis of the tetramer. The
small glycine residue at position 245-α is critical in order
to allow the close interaction of these helices (Figure 5a).
A substitution of glycine for arginine at this position by
the G245R-α mutation would clearly prevent a tight asso-
ciation of the two α subunits in the manner observed in
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Table 1
Missense mutations in E1b subunits and clinical phenotypes of MSUD patients.
Amino acid substitution Enzyme activity* Clinical phenotype Ethnic origin Reference
(% normal)
Group 1 — mutations affecting cofactor binding
R114W-α Unknown Classic Japanese [52]
T166M-α 0 Classic Thai (JLC and DTC, unpublished observations)
R220W-α 0 Classic Caucasian [30]
N222S-α 1.3† Classic Caucasian [53]
Group 2 — mutations affecting hydrophobic cores
M64T-α 6§ Intermediate Caucasian (JLC and DTC, unpublished observations)
G204S-α 0 Classic Caucasian [30]
A208T-α 0 Classic Japanese [52]
T265R-α 0 Classic Canadian [30]
I281T-α 1.4‡ Intermediate Japanese [52]
Group 3 — mutations affecting subunit association
N126Y-β <1§ Classic Unknown [54]
Q145K-α 1.4‡ Intermediate Japanese [52] 
H156R-β 0 Classic Japanese [52] 
A209D-α 27‡ Intermediate Caucasian (JLC and DTC, unpublished observations)
A240P-α 0 Classic Caucasian [30] 
G245R-α 4† Intermediate Hispanic-Mexican [55] 
R252H-α 27‡ Intermediate Caucasian (JLC and DTC, unpublished observations)
F364C-α 0 Classic Hispanic-Mexican [53]
Y368C-α 0 Intermediate Caucasian [55] 
Y393N-α 0 Classic Mennonite [42] [31]
*Unless otherwise indicated, BCKD activity was measured using
fibroblasts or lymphoblasts derived from MSUD patients and normal
subjects. Intact-cell assays were carried out by incubating harvested
cells with α-keto [1–14C] isovalerate under isotonic conditions, and
14CO2 released was measured [43]. The residual BCKD activity is
expressed as a percentage of wild type. †E1b activity in the
recombinant protein carrying the G245R-α or N222S-α mutation was
measured by radiochemical E1b assays using α-keto [1–14C]
isovalerate as a substrate and 2,6-dichlorophenol indophenol as the
electron acceptor [43]. The results were compared to that obtained
with the wild-type E1b protein. ‡The residual BCKD activity was
measured with intact MSUD cells that are compound-heterozygous for
I281T-α/Q145K-α or A209D-α/R252H-α. Thus, the residual activity is
expressed by one or both alleles in each patient. The other allele in the
patient carrying the M64T-α mutation has not been identified. §The
other allele in the patient carrying this mutation is a null-allele.
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the crystal structure. It is rather surprising therefore that
observations indicate that the mutant protein may never-
theless assemble in an imperfect way to produce a par-
tially active enzyme [30]. E1b activity of a recombinant
protein with the glycine to arginine mutation at position
245-α was measured to be approximately 4% compared
with wild-type, and patients carrying this mutation show
an intermediate clinical phenotype (Table 1). 
On the basis of our structure, the two MSUD mutations
A240P-α and R252H-α would both be predicted to disrupt
a network of interactions formed between charged groups
at the N-terminal end of helix 10 (Figure 5a). In the wild-
type enzyme Arg252-α makes a salt bridge with the nega-
tively charged sidechain of Asp237-α as well as with the
sidechain of Glu282-α, which in turn interacts with the
positive end of the dipole of helix 10 through a direct
hydrogen bond with the amino group of Ala240-α. This
extensive network of salt bridges and hydrogen bonds is
probably critical for the precise positioning of helix 10 and
consequently for the formation of the α–α′ interface. The
R252H-α MSUD mutation introduces a shorter histidine
sidechain that might not be able to maintain optimal bonds
with both sidechains of Asp237-α and Glu282-α at the
same time (Figure 5a). The A240P-α mutation, on the
other hand, eliminates the free amino group at the begin-
ning of helix 10 and interrupts the hydrogen bond between
Glu282-α and the imino group of Ala240-α occurring in the
wild-type enzyme. This mutation might also prevent for-
mation of the bond between Glu282-α and the mainchain
amino group at position Ile239-α by steric hindrance. The
A240P-α mutation gives rise to a classic clinical phenotype
with no residual multienzyme complex activity. In con-
trast, R252H-α together with A209D-α (also found at the
α–α′ interface, not shown) are the least severe mutations
known to cause MSUD. These two mutations occur in
compound-heterozygous patients that display almost 30%
residual multienzyme complex activity (Table 1).
His156-β is probably critical for the close interaction
between the two β subunits. Like a ‘knob in a hole’, the
sidechain of His156-β in one β subunit is tucked into an
interface pocket formed by the other β subunit, packing
against the sidechains of Phe153-β′ and Pro282-β′
(Figure 5b). In addition, His156-β makes a hydrogen bond
with the mainchain carbonyl of Thr284-β′. Although the
arginine sidechain, introduced by the H156R-β mutation
at this position, could potentially have favorable interac-
tions with Glu151-β′ at the bottom of the pocket this
might lead to loss of a favorable interaction between
Glu151-β′ and the sidechain of Trp227-β′ (Figure 5b). In
addition, a specific hydrogen bond between the sidechain
of His156-β and the mainchain carbonyl group of
Thr284-β would be lost by the substitution. The interface
pocket accommodating the His156-β sidechain might
therefore not be able to accommodate the larger sidechain
of an arginine residue in a satisfactory way and the histi-
dine to arginine mutation at this position thereby prevents
association of the β subunits and assembly of an active
tetramer, causing a classic form of MSUD.
Another interface residue altered in some MSUD patients
is Asn126-β, which appears to be involved in forming a
network of hydrogen bonds that stabilizes the conforma-
tion of the polypeptide in two regions in the β subunit,
around positions Asn126-β and Lys182-β (Figure 3c).
These regions are critical for K+ binding at site 2 (see
above) and might also be important for subunit associa-
tion. The sidechain of Asn126-β forms hydrogen bonds
with the imino group of Gly128-β and with the sidechain
of Arg118-β. The MSUD substitution N126Y-β would
dramatically affect this region because of the larger size of
the newly introduced sidechain. The favorable interaction
between Arg118-β and the mainchain carbonyl of
Lys182-β is likely to be disrupted with further serious
consequences because the mainchain carbonyl groups of
residues 181-β, 183-β as well as 128-β ligate the K+ at site
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Figure 4
MSUD mutations affecting cofactor binding
and the hydrophobic core in human E1b.
(a) The R114W-α, R220W-α and N222S-α
mutations each affect residues that are directly
involved in binding the cofactor phosphates
and the associated magnesium ion. Asn222-α
is a conserved residue in the superfamily of
ThDP-utilizing enzymes and is a part of its
sequence fingerprint motif (GDG(X)22–30NN).
Also shown is the primary phosphorylation site
at Ser292-α [26]. (b) The sites of the T265R-
α and I281T-α mutations appear to occur in
the same hydrophobic cluster of the α subunit.
These mutations are likely to prevent optimal
packing in the hydrophobic core. This figure
was made using MOLSCRIPT [48] and the
Raster3D suite [49].
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2. Interfering with this K+ site has yet further implications
because the sidechain of Asn183-β is in contact with the
mainchain of the α subunit at position 369 adjacent to
Tyr368-α (which is the site of another MSUD mutation;
see below) at the α–β interface. The structural effects of
the asparagine to tyrosine substitution at position 126-β
correlate well with the observation that this mutation
causes severe MSUD.
The ‘Mennonite region’
There are three MSUD missense mutations that map onto
the extended small C-terminal domain protruding from the
bulk of the α subunit (Figure 6a). This domain has a differ-
ent size in different E1 heterotetramers (Figure 2) but
seems to function as support for the two β subunits extend-
ing the interaction between the α and β subunits. This
small domain of each α subunit is in contact with both
β subunits (Figure 6). The interface contacts are to a large
extent hydrophobic in nature with a notable feature being
an array of aromatic sidechains from the α subunit side
packed against an array of aromatics from the β′ subunit
(Figure 7). All three MSUD mutations in this part of the
α subunit occur in the ‘aromatic α array’ and substitute an
aromatic residue for a smaller and non-aromatic residue.
This includes the frequent tyrosine to asparagine mutation
at position 393-α found in the US Mennonite population
[31,32], in which the prevalence of this mutation is 1 in 176
live births as a result of consanguinity [19,33].
Tyr393-α is packed in between two aromatic residues,
Trp330-β′ and Phe324-β′, of the β′ subunit and forms two
hydrogen bonds via its hydroxyl group with Asp328-β′ as
well as His385-α (Figure 6b). The tyrosine to asparagine
mutation at position 393-α introduces a much smaller and
polar asparagine sidechain that would be unable to com-
pensate for the extensive contact made by the native
tyrosine sidechain. 
The sidechain of Tyr368-α, another member of the aro-
matic α array affected by MSUD mutations, fits into a
surface pocket on the β subunit (Figure 6a) formed by the
sidechains of residues Asn183-β, Lys161-β and Pro259-β
and the mainchain atoms of Gly159-β and Ile160-β. The
hydroxyl group is then able to act as both hydrogen-bond
acceptor and donor making hydrogen bonds to a main-
chain carbonyl group (160-β) and a mainchain imino group
(Gly159-β). These specific interactions would not be
formed by the smaller cysteine sidechain resulting from
the tyrosine to cysteine mutation at position 368-α. 
Phe364-α, the third member of the aromatic array
changed into a non-aromatic in certain MSUD patients,
makes extensive hydrophobic interactions with the
sidechains of Leu363-α, Leu375-α, Gln379-α and
Leu382-α, which contribute to the compact hydrophobic
core within the small C-terminal domain of the α subunit.
In addition, these residues are also part of the interface to
the β subunit where the sidechains of Leu362-α, Leu363-α
and Phe364-α are tightly packed against the sidechain of
Tyr313-β′ (Figure 6a). The phenylalanine to cysteine
MSUD mutation at position 364-α is likely to affect α–β′
subunit interactions by causing defects in the subunit
interface but might have more profound consequences for
the folding of the small C-terminal domain itself.
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Figure 5
MSUD mutations affecting subunit interactions. For clarity, chains are
shown as polyglycine plus selected sidechains only. (a) Mutations
close to the interface between the α subunits of the E1b tetramer.
Mutations A240P-α and R252H-α are likely to prevent formation of the
network of bonds between charged groups at the N-terminal end of
helix 10. These interactions might be important for the precise
positioning of the helix and hence for formation of the interface
between the α subunits. The G245R-α mutation would introduce a
large sidechain at a position where a small sidechain is required in
order to allow the close approach of the interface helices α10 and α10′.
(b) Stereoview of the site of the H156R-β mutation at the interface
between the β subunits. The precise fit of the histidine sidechain in the
interface pocket formed by the opposite β subunit cannot be obtained
with the larger sidechain of an arginine residue introduced by the
MSUD mutation. This figure was made using MOLSCRIPT [48] and
the Raster3D suite [49].
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The aromatic to non-aromatic mutations in the small
C-terminal domain of the α subunit are of particular inter-
est because they have a dramatic effect on the structural
integrity of the protein as a whole by impairing the
process of tetramer assembly. We have shown previously
that the folding and assembly of mammalian E1b het-
erotetramers is entirely dependent upon chaperonins
GroEL/GroES either in E. coli [11] or in vitro [12]. More-
over, the chaperonin-mediated α2β2 assembly proceeds
through an αβ heterodimeric intermediate [30], which can
be isolated as a relatively stable species from E. coli under
certain growth conditions [12]. Our recent pulse-chase
data shows that Y393N-α, F364C-α and Y368C-α muta-
tions markedly reduce the assembly rate of the normal β
subunit with the mutant α [30]. On the other hand,
expression studies in E. coli indicate that in the presence
of over-producing chaperonins GroEL/GroES, Y393N-α
and F364C-α subunits are capable of assembly with the
normal β subunit into stable heterodimers, but the latter
are unable to convert to active heterotetramers [30].
Under similar conditions, the wild-type α subunit assem-
bles with β subunits into active heterotetramers. As for
the Y368C-α mutation, the mutant α subunit and the
normal β appear to be capable of forming both heterote-
tramers and heterodimers [30].
From the structural analysis combined with the biochemi-
cal studies emerges a picture of a probable assembly
pathway of the human E1b tetramer in vivo. The pro-
posed assembly proceeds from single subunits, see
Figure 7, via heterodimers αβ and α′β′ to the final het-
erotetramer. The Y393N-α mutation apparently blocks
this assembly midway because it leads exclusively to for-
mation of heterodimers. A single heterodimer of this type
would correspond to association of the α subunit with the
β subunit and not the β′ subunit because the α–β′ inter-
action is impaired by the Y393N-α mutation. In effect, the
Y393N-α mutation blocks the final step of the assembly
by preventing the interaction between the two het-
erodimers (Figure 7). The resulting heterodimers would
be inactive because the active sites in which the cofactors
are bound are formed in the last step of the pathway
through assembly of the αβ and α′β′ dimers.
The F364C-α mutation can be predicted to have similar
effects as the Y393N-α mutation has on tetramer assembly
because it affects the same α–β′ and α′–β interfaces. This
is also supported by the results of the chaperonin-assisted
assembly studies [30].
The Y368C-α mutation is distinctly different from the
F364C-α and Y393N-α mutations because it affects differ-
ent interfaces (α–β and α′–β′) and would seem to impair
the first step in the assembly pathway in Figure 7. It also
appears to be less severe, however, because it does not
completely prevent assembly of the tetramer.
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Figure 6
Mutations affecting subunit interactions between α and β subunits.
(a) Mutations in the small C-terminal domain of the α subunit at the
interface with the two β subunits. The C-terminal domain is shown with
a coil representation of the backbone with selected sidechains. The
β subunits are shown as semi-transparent surfaces, in yellow for the
β′ subunit and in red for the β subunit. Some sidechains in the
β subunits that are forming the interface to the α subunit are shown
beneath the surface. Note that the α subunit makes contacts with both
β subunits and also note the prevalence of aromatic residues at the
subunit interface. The sites of the three MSUD mutations in this region
of the α subunit, F364C-α, Y368C-α and Y393N-α, are highlighted. All
three mutations are substitutions of aromatic residues involved in the
interface to a β subunit, Tyr368-α is in contact with the β subunit (α–β
interface) whereas Phe364-α and Tyr393-α contact the β′ subunit
(α–β′ interface). (b) Close up stereoview of Tyr393-α (the site of the
‘Mennonite’ mutation) and its vicinity at the interface between the small
C-terminal domain of the α subunits and the β′ subunit. Tyr393-α is
packed in between the sidechains of Phe324-β′ and Trp330-β′ with its
hydroxyl group making hydrogen bonds with the sidechains of His385-α
and Asp328-β′. The Y393N-α mutation is the most frequently observed
mutation that causes MSUD [31,42]. This figure was created using
GRASP [51], MOLSCRIPT [48] and the Raster3D suite [49].
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Interaction with other components in the multienzyme
complex
The human E1b component interacts with a number of
other components within the multienzyme complex: the
binding domain and lipoyl domain of E2b as well as the
specific protein kinase and phosphatase that control the
activity of E1 through (de)phosphorylation. It has been
shown previously that an E1 tetramer binds only one copy
of the E2 binding domain with the binding site located on
the β subunits [34,35]. This suggests that the binding site
is located at or close to the twofold axis on the β subunits.
Our reconstitution experiments employing different con-
structs of human E1b now provide more direct evidence
supporting binding at this location of the tetramer. The
results indicate that, under the same conditions, an E1b
tetramer with an N-terminal His6-tag on the α subunit
readily forms a complex with the E2b 24-mer, whereas an
E1b heterotetramer that carries a C-terminal His6-tag on
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Figure 7
The proposed assembly pathway of the human
E1b tetramer and the possible effects of
mutations F364C-α, Y368C-α and Y393N-α
on the assembly. The tetramer probably
assembles through the formation of
intermediate heterodimers (see text). Assembly
of mutant proteins carrying the Y393N-α
mutation results exclusively in the formation of
heterodimers that can be predicted to
correspond to αβ and α′β′ dimers because the
α–β′ and α′–β interaction is impaired by the
Y393N-α mutation. The same is probably the
case for the F364C-α mutation. The Y368C-α
mutation would have distinctly different effects
on tetramer assembly because it occurs at
different interfaces (α–β and α′–β′) compared
with the other two mutations. The figure was
created using MOLSCRIPT [48].
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the β subunit cannot bind to E2b (data not shown). The
latter construct was used to express protein for the struc-
ture determination and although the His6 tags are invisible
in our electron-density maps there is visible density up to
the last residue preceding the His6 tag at the C termini of
the β subunits. It is interesting that the proposed binding
of the E2 binding domain to E1 (Figure 8a) is analogous to
the binding of a single copy of this domain to the E3
dimer as seen previously in the structure of Bacillus
stearothermophilus E3 in complex with the E2 binding
domain (Figure 8b) [36].
Given our ability to model approximate interactions of dif-
ferent multienzyme components, we can now assemble the
building blocks together in an overall picture of the human
E1b multienzyme complex analogs because examples of
all components have been structurally characterized
[4,16,37,38]. Combining this with a simple model of the
mutual arrangement of components in multienzyme com-
plexes that emerged from early electron microscopy work
[39], we can arrive at the hypothetical model of a BCKD
complex shown in Figure 8c. The model includes an E2
core with 24 subunits arranged as a cube with 432 (octahe-
dral) symmetry as seen for the first time for the core of Azo-
tobacter vinelandii pyruvate dehydrogenase [4]. An E1
tetramer is placed above each of the 12 edges of the cubic
core with the twofold axis of the E1 molecule coinciding
with the twofold axes of the core and the β subunits with
the associated E2 binding domains oriented towards the
core. In an analogous way an E3 dimer in complex with an
E2 binding domain is placed at the fourfold axis above
each of the six faces of the cubic core. The lipoyl domains
are placed in the space between the E1 and E3 molecules
allowing free access to the respective active sites. The
resulting complex has a molecular mass close to four
million Da and an overall diameter of approximately 400 Å.
As intact α-ketoacid dehydrogenase multienzyme com-
plexes resist crystallization, our attempts to obtain a high
resolution overall picture of these macromolecular assem-
blies focused on structural studies of the individual com-
ponents providing pieces to a composite picture as the
one outlined above. Further advances using electron
microscopy, nuclear magnetic resonance (NMR), crystal-
lography and biochemical techniques will continue to
provide more refined models. These complexes are an
elegant combination of a highly symmetric core sur-
rounded by flexible ‘arms’ to which dozens of large addi-
tional enzymes are attached with variations in
stoichiometry. One might particularly appreciate the sub-
strate CoAs, which have to navigate around the swirling
peripheral proteins to enter the hollow core of the
complex [40] in order to retrieve a precious acyl group,
and then to make the journey out of the complex to assure
the proper delivery of this group to other critical, yet
simpler, components in the mitochondrial matrix.
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Figure 8
Assembly of the BCKD complex. (a) Interaction between E1 and the
binding domain of E2. Human E1b is shown on the left with the
proposed binding site of the E2 binding domain at the top of the
tetramer close to the C termini of the β subunits. Recombinant protein
carrying a His-tag at the C termini of the β subunits is unable to bind
the E2 binding domain. (b) The proposed position of the binding
domain at the twofold axis of the E1 tetramer is analogous to the
binding of the E2 binding domain at the twofold axis of the E3 dimer,
as seen in the structure of Bacillus stearothermophilus E3 in complex
with the E2 binding domain [36]. (c) Hypothetical composite model of
a branched-chain dehydrogenase multienzyme complex (described in
the text).
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Biological implications
Mutations in components of the α-ketoacid dehydroge-
nase multienzyme complex can lead to potentially severe
disorders in humans, including maple syrup urine
disease (MSUD). We determined the crystal structure of
a component (the E1b component) of the branched-
chain α-ketoacid dehydrogenase multienzyme complex
from humans.
The structure of human 2-oxoisovalerate dehydrogenase
has enabled us to provide a detailed explanation for all
the 19 point mutations of α-ketoacid dehydrogenase
(E1b) that are known to be responsible for MSUD in
human patients. In essentially all instances the severity
of the disease corresponds well with the predicted effect
of the mutation on the structure, stability, and cofactor or
K+ binding by the enzyme. In the severe cases cofactor
binding is essentially prohibited, or proper assembly
made impossible. In these cases our structural studies
provide profound insight, but the structure does not
easily lend itself as a platform for the development of
small therapeutic agents that assist in treatment for the
disease.
For some of the milder mutations, however, the human
E1b structure presented here might lend itself perhaps
to the discovery of compounds that could be therapeuti-
cally useful for several of these less severe forms of
MSUD, even if these are caused by entirely different
mutations. The principle of the proposed approach is
that mutations such as M64T-α, I281T-α and R252H-α
probably lead to a significant but not dramatic decrease
in the stability of E1b. E1b heterotetramers with these
mild MSUD mutations might be recovered by interac-
tions with small molecules. Because tightly binding
small molecules are able to increase the stability of pro-
teins significantly during or after folding, the discovery
of low molecular weight compounds with high affinity
for human E1b that do not adversely affect the catalytic
machinery of the enzyme, could be a starting point for
the development of useful therapeutic agents. In partic-
ular, patients with the intermittent forms of the disease,
who, therefore, would not require a life long use of ther-
apeutic compounds, might benefit from such an
approach. This approach might be generally applicable
to other genetic diseases in which loss of protein stability
causes milder forms of the disease (for instance, several
forms of β-galactosialidosis are caused by relatively mild
mutations in the human protective protein [41]).
Materials and methods
Construction of a vector for the expression of human E1 with
a His6 tag at the C terminus of the β subunit
To facilitate vector construction, an NcoI site was engineered into the
N terminus of the mature human α sequence using polymerase chain
reaction (PCR) amplification. This resulted in the incorporation of an
extra glycine immediately upstream of the N-terminal serine residue. An
NcoI/EcoRI fragment encoding the N-terminal sequence of the
α subunit was restricted from the PCR product. An EcoRI/BamHI frag-
ment containing the downstream sequence of the subunit was excised
from the previously described EBO-bhE1a vector [42]. To generate the
insert for the mature β subunit, a sequence coding for the His6 tag was
incorporated immediately 3′ to the C-terminal tyrosine codon. The
β-His6 sequence was inserted into the NcoI/EcoRI-digested pKK233-2
vector from Amersham Pharmacia (Piscataway, NJ). The NcoI/EcoRI
and the EcoRI/BamHI fragments from the a subunit along with the
BamHI/ScaI gene cartridge containing the pTac promoter and the
β-His6 sequence were ligated into a NcoI/ScaI-digested pTrcHisB
vector from Invitrogen (Carlsbad, CA). The resultant vector p-hE1-His6
encodes an untagged α sequence and the C-terminal His6-taggedβ sequence of human E1b.
Expression and purification of recombinant human E1b protein
The p-hE1-His6 plasmid and pGroESL plasmid overproducing chaper-
onins GroEL/ES were cotransformed into GroESts CG-712 E. coli,
and cells were induced with IPTG for hE1b expression as described
previously [30,34]. The overexpression of chaperonins GroEL/ES in
the host cells was essential for efficient expression of hE1b. The
recombinant human E1b-His6 protein was extracted from cell lysates
with Ni-NTA resin (Qiagen, Valencia, CA), and eluted with a
15–250 mM imidazole gradient in a buffer containing 50 mM KPi,
pH 7.5, 500 mM NaCl, 10 mM β-mercaptoethanol, 1 mM benzamidine,
1 mM PMSF and 5% glycerol. The Ni-NTA extracted protein was
applied to a Resource Q FPLC column and eluted with a 50–300 mM
KCl gradient in the above-mentioned buffer minus NaCl, and with
2 mM DTT replacing β-mercaptoethanol. The eluted protein was
further purified on a Superdex 200 FPLC gel-filtration column equili-
brated with 50 mM Hepes, pH 7.5, 250 mM KCl, 2 mM DTT and 5%
glycerol. The purified human E1b-His6 protein was concentrated on
Ultra free-15 concentrator (Millipore, Bedford, MA) to a concentration
of 20 mg/ml. The protein was homogenous as judged using SDS-
PAGE and Coomassie blue staining. The final specific activity of the
purified E1b-His6 protein was 79 mU/mg as assayed radiochemically
with 2,6-dichlorophenol indophenol as an electron acceptor [43].
Crystallization
After purification, the protein was kept in 0.1 M MES pH 7.5, 0.25 M
KCl, 10% glycerol, 1 mM ThDP, 10 mM MgCl2 and stored at –80°.
The protein was crystallized using sitting drops with 35–40%
ethanol, 0–2% PEG8000, 0.1 M MES pH 7.5 as a reservoir solution.
Upon setting up crystallization drops, the protein solution, containing
about 18 mg/ml protein, 0.1 M MES pH 7.5, 0.25 M KCl, 10% glyc-
erol, 1 mM ThDP, 10 mM MgCl2 and 1 mM inhibitor (either 
2-chloroisocaproate or clofibrate), was usually mixed with the reser-
voir solution in a ratio between 1:0.1 and 1:1 protein solution:reser-
voir solution. In some cases the protein solution was not mixed with
reservoir solution and crystallization proceeded through free diffusion
of ethanol from the reservoir to the sitting drop. In either case, crystal-
lization was rapid and the crystals reached their final size in one day.
The crystals grew as long thin rods up to 20 mm in thickness.
Attempts to cryoprotect crystals using artificial cryo solutions were
often not very successful and severely reduced quality of diffraction.
Eventually, the crystals could be frozen satisfactorily using cryo solu-
tion made by mixing reservoir solution and 100% glycerol in a ratio of
4 to 1. Because of continuous evaporation of ethanol, care was taken
to rapidly remove crystals from the crystallization drop to the cryo
solution and then freeze them either in liquid nitrogen for storage or
directly in a nitrogen stream during crystal mounting on a detector.
Crystals left in crystallization drops beyond a few weeks would deteri-
orate (‘rubberize’) and show no longer a diffraction pattern when
exposed to the X-ray beam. 
Data collection and structure determination
Data used for structure solution were collected using synchrotron
sources at ESRF beamline ID02 (data set 1, co-crystallization with
α-chloroisocaproate) and APS beamline 19-ID (data 2, co-crystallization
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with clofibrate). Data collected from selenomethionine crystals suffered
from crystal decay, despite cryo cooling, and did not allow successful
phasing using MAD methods (unpublished observations). The structure
could eventually be determined using molecular replacement methods
(MR) using the previously determined structure of P. putida E1b [16] as
a search model. An initial MR [44] solution was found using data set 1
but improved maps were obtained using data set 2 at 2.7 Å resolution.
Iterative model building using the program O [45] and refinement, using
X-PLOR [46] and at later stages using CNS with simulated annealing
torsion angle refinement using maximum-likelihood target function [47],
resulted in a model of residues 7–301 and 314–400 (out of 400) in the
α subunit and residues 17–342 (out of 342 + His-tag) in the β subunit
(Table 2). Residues missing in the current model were disordered and
poorly or not visible in density maps. The asymmetric unit of the final
model contains one α subunit, one β subunit, 48 water molecules, one
ThDP cofactor molecule, one Mg+ and two K+.
Accession numbers
The coordinates have been deposited in the Protein Data Bank with
accession code 1DTW.
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